Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Umbilical cord-derived mesenchymal stem cells (uMSCs) are an investigational cell therapy developed by researchers at the Second Hospital of Shandong University for the treatment of ankylosing spondylitis (AS). These cells are derived from human umbilical cord or placenta and administered via intravenous infusion. The therapy functions through potent immunomodulatory mechanisms, including the inhibition of B cell differentiation and T cell activation, the induction of regulatory T cells (Tregs), and the suppression of Th17 cell generation and interleukin-17 (IL-17) secretion. A Phase II clinical trial (NCT01420432) evaluated the safety and efficacy of these uMSCs at a dose of 1.0E+6 MSC/kg, often in combination with disease-modifying antirheumatic drugs (DMARDs), demonstrating a favorable safety profile and clinical improvement in disease activity and symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on umbilical cord-derived mesenchymal stem cells (Shandong University).